News | Proton Therapy | September 15, 2015

Mayo Clinic Begins Treatments with Hitachi Probeat-V Proton Beam Therapy System

Minnesota facility first to install system with Discrete Spot Scanning capability; Arizona campus to follow suit

Hitachi, Probeat-V, proton beam therapy, Mayo Clinic, Rochester, Minnesota

Image courtesy of Hitachi Ltd.

September 15, 2015 — Hitachi Ltd. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for commercial supply of the new Probeat-V system designed and developed for Mayo Clinic in Rochester, Minnesota. Treatments began in late June and the first patient treatment was completed in August 2015.

The Probeat-V is a state-of-the-art proton beam therapy system used to deliver Hitachi’s Discrete Spot Scanning capability to each treatment room. The 190-degree half gantries provide efficient yet spacious treatment room environments; patients no longer need to be positioned inside a 360-degree gantry, as all treatment angles are achieved by a 6-degree of freedom (DOF) couch. A 30 percent smaller treatment spot size, achieved through refinements in nozzle design, enables the system to achieve highly precise treatments. In addition, installation and commissioning activities are already underway at a second Mayo facility in Phoenix, Arizona, with treatments scheduled to start in the spring of 2016.

Mayo Clinic treats more than 1.3 million patients annually from all 50 states and 143 countries. Mayo Clinic has maintained its position as one of the top hospitals in U.S. News & World Report rankings for more than 20 years.

The Probeat-V system also offers:

  • Beam matching (within 5 percent) technology allowing patients to be treated in any room at any time;
  • Integrated setup rooms to increase patient throughput. Although patients’ visits may often take between 15 to 30 minutes, the time required for irradiation is usually only a few minutes. At Mayo Clinic, setup rooms allow patients to be stabilized and pre-positioned offline, optimizing treatment room utilization and shortening patients’ visits; and
  • An improved user interface, co-developed with Mayo Clinic.

For more information: www.hitachimed.com

Related Content

IBA Releases Razor Nano Ionization Chamber
News | Proton Therapy | September 22, 2017
September 22, 2017 — IBA (Ion Beam Applications S.A.) announced the release of the Razor Nano Chamber, the smallest a
Penn Medicine Treats World's First Patient on Varian's Halcyon System
News | Radiation Therapy | September 22, 2017
September 22, 2017 — Varian Medical Systems announced a patient at Penn Medicine, with head & neck cancer, became
BrainLAB Announces FDA Clearance For Two New Indication-Specific Radiosurgery Software Applications
Technology | Treatment Planning | September 21, 2017
Brainlab announced that it has received U.S. Food and Drug Administration (FDA) clearance for Elements Spine SRS and...
Accuray Showcases CyberKnife and Radixact Systems at ASTRO 2017
News | Radiation Therapy | September 21, 2017
Accuray Inc. announced that data and first-hand experience with its advanced CyberKnife and Radixact Systems will be...
RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init